U.S. markets open in 7 hours 12 minutes

IDEAYA Biosciences, Inc. (IDYA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.71-0.40 (-3.05%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close13.11
Bid0.00 x 1200
Ask0.00 x 800
Day's Range12.42 - 13.18
52 Week Range2.95 - 19.97
Avg. Volume147,124
Market Cap368.952M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.26
Earnings DateAug 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.22
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO

    The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 23) * Acceleron Pharma Inc (NASDAQ: XLRN) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) * Beigene Ltd (NASDAQ: BGNE) * Blueprint Medicines Corp (NASDAQ: BPMC) * Cardiff Oncology Inc (NASDAQ: CRDF) * Castle Biosciences Inc (NASDAQ: CSTL) * Horizon Therapeutics PLC (NASDAQ: HZNP) (moved on positive sell-side comment on its thyroid eye disease drug) * InVitae Corp (NYSE: NVTA) * Myovant Sciences Ltd (NYSE: MYOV) * Novo Nordisk A/S (NYSE: NVO) * Pacific Biosciences of California Inc (NASDAQ: PACB) * SpringWorks Therapeutics Inc (NASDAQ: SWTX) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) * Vaxcyte Inc (NASDAQ: PCVX)Down In The Dumps (Biotech Stocks Hitting 52-Week Lows Sept. 23) * Alector Inc (NASDAQ: ALEC) * Athira Pharma Inc (NASDAQ: ATHA) * Amarin Corporation plc (NASDAQ: AMRN) * BELLUS Health Inc (NASDAQ: BLU) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT) * Genetron Holdings Ltd - ADR (NASDAQ: GTH) * Genfit SA (NASDAQ: GNFT) * Gritstone Oncology Inc (NASDAQ: GRTS) * Histogen Inc (NASDAQ: HSTO) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) * Neos Therapeutics Inc (NASDAQ: NEOS) * Neurobo Pharmaceuticals Inc (NASDAQ: NRBO) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * PainReform Ltd (NASDAQ: PRFX) * Pandion Therapeutics Inc (NASDAQ: PAND) * RA Medical Systems Inc (NYSE: RMED) * Renalytix AI PLC (NASDAQ: RNLX) * Teligent Inc (NEW JERSEY) (NASDAQ: TLGT) * Tricida Inc (NASDAQ: TCDA) * Vaccinex Inc (NASDAQ: VCNX)Stocks In Focus Luminex Snags $683.5K BARDA In Funding For COVID-19 Antibody Test Luminex Corporation (NASDAQ: LMNX) said it has received an award of $683,500 from the Biomedical Advanced Research and Development Authority to support the enhancement of its xMAP SARS-CoV-2 Multi-Antigen IgG Assay. The company intends to submit this enhanced serology assay for an emergency use authorization when the project is completed."The xMAP SARS-CoV-2 Multi-Antigen IgG Assay detects antibodies to three different viral antigens -- the spike protein, nucleocapsid, and receptor-binding domain -- to assess if a person has been infected with SARS-CoV-2," the company said.In after-hours trading, the stock was down 1.63% at $27.40.Lexicon Announces Exchange Of Notes In Bid To Reduce Indebtedness Lexicon announced privately negotiated exchange agreements with certain holders of its 5.25% convertible senior notes due 2021 under which the holders have agreed to exchange $62.55 million in notes for $41.03 million in cash and 8.75 million shares of Lexicon's common stock.The transactions are expected to close by Sept. 28. Following the closings, $24.95 million in aggregate principal amount of the notes will remain outstanding, the company said.This transaction, along with other debt reductions, will have reduced Lexicon's outstanding debt by approximately 90% since June 30.The stock was trading 4.64% higher at $1.58 premarket Thursday.Ideaya Expands Oncology Study Collaboration With Pfizer Ideaya Biosciences Inc (NASDAQ: IDYA) said it has expanded its clinical trial collaboration and supply agreement with Pfizer Inc. (NYSE: PFE) for an IDEAYA-sponsored clinical combination study of IDE196, to which Pfizer has exclusive worldwide rights.The study will evaluate IDE196 and crizotinib combination therapy in patients with solid tumors having GNAQ or GNA11 mutations, including metastatic uveal melanoma, skin melanoma, lung cancer and colorectal cancer.See also: The Week Ahead In Biotech: Conference Presentations, IPOs In The Mix Axsome Migraine Drug Found Superior to Active Comparator Rizatriptan Axsome Therapeutics Inc (NASDAQ: AXSM) announced new data from the Phase 3 MOMENTUM study of AXS-07, which showed rapid onset of action and reduced symptom recurrence in acute treatment of migraine, as compared to the potent active comparator rizatriptan marketed by Merck & Co., Inc. (NYSE: MRK).Co-Diagnostics Plans Launch Of Triplet Test In First Week of October Co-Diagnostics Inc (NASDAQ: CODX) said its Logix Smart ABC Test for diagnosing influenza A, influenza B and COVID-19 is expected to be ready for launch to U.S. CLIA laboratory customers the first week of October.View more earnings on IBBThe stock was trading 6.32% higher at $14.30 premarket.Ascendis Files For Pediatric Growth Hormone Deficiency Drug In Japan Ascendis Pharma A/S (NASDAQ: ASND) said it has filed a clinical trial notification with the Pharmaceuticals and Medical Devices Agency in Japan to initiate a Phase 3 riGHt trial of TransCon hGH, a long-acting prodrug of somatropin, for the treatment for pediatric growth hormone deficiency.OraSure's Saliva Collection Device Included In EUA For Quadrant's COVID-19 Test OraSure Technologies, Inc. (NASDAQ: OSUR) said its ORAcollect RNA saliva collection device has been included in the FDA EUA granted to Quadrant Biosciences Inc. for a COVID-19 laboratory test.This is the sixth EUA to include a collection device from the company's DNA Genotek subsidiary and the first to exclusively utilize a saliva collection method, OraSure said. OraSure shares were trading 2.93% higher to $11.95 premarket Thursday.Aytu Postpones Q4 Earnings Release Aytu Bioscience Inc (NASDAQ: AYTU), which was scheduled to report its fiscal year fourth-quarter results Thursday after the close, said it will reschedule the earnings call to allow additional time to finalize financial statements due to the additional workload created by the recently completed acquisition of Innovus Pharmaceuticals and to accommodate scheduling needs related to COVID-19.The stock was down 3.91% to $1.23 in after-hours trading.Offerings Gilead Sciences, Inc. (NASDAQ: GILD) priced its underwritten public offering of senior unsecured notes in an aggregate principal amount of $7.25 billion, consisting of seven tranches. The offering is expected to close Sept. 30, subject to customary closing conditions.The company said it intends to use the net proceeds to fund the cash portion of the consideration for buying Immunomedics, Inc. (NASDAQ: IMMU) and also to retire debt.The stock was trading slightly positive premarket at $63.10. On The Radar IPOs Dallas, Texas-based Taysha Gene Therapies, Inc. priced its upsized initial public offering of 7.87 million shares of its common stock at $20 versus the estimated price range of $18-$20.The shares of the company -- which is engaged in the development of AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system -- will begin trading on the Nasdaq under the ticker symbol "TSHA."Related Link: Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates See more from Benzinga * The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma * The Daily Biotech Pulse: Legal Relief For Evolus, Fulgent to Join S&P SmallCap 600, AIM ImmunoTech's Positive Cancer Drug Readout(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations
    PR Newswire

    IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, today announced that it has expanded its clinical trial collaboration and supply agreement with Pfizer Inc. (NYSE: PFE) for an IDEAYA sponsored clinical combination study of IDE196, a Protein Kinase C (PKC) inhibitor, and crizotinib, a cMET inhibitor to which Pfizer has exclusive worldwide rights. The study will evaluate IDE196 and crizotinib combination therapy in patients with solid tumors having GNAQ or GNA11 mutations (GNAQ/11), including metastatic uveal melanoma (MUM), skin melanoma, lung cancer and colorectal cancer.

  • Billionaire Ken Griffin Snaps Up These 3 “Strong Buy” Stocks

    Billionaire Ken Griffin Snaps Up These 3 “Strong Buy” Stocks

    As fears of a tech bubble and stretched valuations become the talk of the town, investors are turning to Wall Street titans for guidance, namely Ken Griffin. Founding hedge fund Citadel in 1990, the firm now boasts over $35 billion worth of assets under management.As a 19-year-old sophomore at Harvard University, Griffin began trading from his dorm room with a fax machine, computer and phone. Now, the CEO of Citadel, whose net worth stands at $15.5 billion, is known as one of the Wall Street greats. Looking at the fund’s performance during the COVID crisis, it’s even more clear why Griffin has legendary status.Unlike the average hedge fund, which had a negative return of between 3-4% in the first half of 2020, Citadel’s flagship Wellington fund saw its returns land between 13-14% for the same period.Bearing this in mind, we wanted to take a closer look at three stocks Citadel snapped up recently. Using TipRanks’ database, we found out that each ticker has earned a “Strong Buy” consensus rating from the analyst community. Not to mention all three of them boast massive upside potential.AVEO Pharmaceuticals (AVEO)Hoping to provide better outcomes for patients, AVEO Pharmaceuticals advances targeted medicines for oncology and other unmet medical needs. Following an important regulatory milestone, it’s no wonder all eyes are on this healthcare name.Griffin is among those singing AVEO’s praises. Increasing its holding by a whopping 2,357%, Citadel bought up 383,720 shares in Q2. With the total position now landing at 400,003 shares, it is valued at $1,824,013.H.C. Wainwright analyst Swayampakula Ramakanth reminds investors that on June 1, the FDA accepted the NDA for tivozanib, the company's lead candidate, for review, based on the fact that the TIVO-3 study reported positive final overall survival (OS) data. In the study, AVEO’s therapy was compared to sorafenib, marketed as Nexavar by Bayer, for the treatment of advanced renal cell carcinoma (RCC) in the third and fourth-line settings.Looking more closely at the data, which was presented at the ASCO 2020 virtual meeting, the final OS analysis resulted in an overall hazard ratio (HR) of 0.97, which favored tivozanib. Ramakanth was “encouraged” by the OS results as they “suggest tivozanib at least has a similar overall relative risk of deaths compared to sorafenib.”“Considering that TIVO-3 study met both the primary endpoint of progression free survival (PFS) and the secondary endpoint of overall response rate (ORR), with comparable OS to the active comparator, we believe tivozanib would likely get a green light for the U.S. approval, which could be a major catalyst in the next 12 months,” Ramakanth opined.Adding to the good news, the dose escalation for the Phase 1b/2 DEDUCTIVE study, evaluating tivozanib in combination with durvalumab, a monoclonal antibody against PD-L1 marketed as Imfinzi by AstraZeneca in hepatocellular carcinoma (HCC), has been wrapped up, with it progressing to Phase 2. As the CDC estimates about 33,000 patients suffer from liver cancer every year in the U.S., Ramakanth sees an additional opportunity.To this end, Ramakanth rates AVEO a Buy rating along with a $12 price target. Should his thesis play out, a potential twelve-month gain of 163% could be in the cards. (To watch Ramakanth’s track record, click here)Other analysts don’t beg to differ. 3 Buy ratings and no Holds or Sells have been assigned in the last three months. So, the word on the Street is that AVEO is a Strong Buy. The $15 average price target is more aggressive than Ramakanth’s and implies 229% upside potential. (See AVEO stock analysis on TipRanks)IDEAYA Biosciences (IDYA)Next up we have IDEAYA Biosciences, an oncology-focused precision medicine company that develops targeted therapeutics by using molecular diagnostics. Based on the strength of its technology, this name has scored several fans.Reflecting a new position for Griffin's Citadel, the fund pulled the trigger on 248,005 shares in Q2. As for the value of this holding, it comes in at $2,881,818. Writing for Northland Capital, analyst Tim Chiang believes shares are “undervalued based on the future potential of its precision medicine oncology pipeline, which targets specific biomarkers.” Expounding on this, he stated, “IDEAYA is applying its capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets.”Part of what makes IDYA a stand-out, in Chiang’s opinion, is the fact that its preclinical programs use its synthetic lethality (SL) platform, which targets tumors with MTAP gene deletion and homologous recombination deficiency (HRD) including BRCA mutations.“We believe the longer-term upside potential with IDYA shares is significant given the potential utility of SL. The first clinically validated SL gene pair was PARP-BRCA1/2, and based on the efficacy of PARP inhibitors, the SL approach to treating cancer has achieved substantial commercial validation,” the analyst explained.To back this up, Chiang points out that several PARP inhibitors have already been approved for the treatment of tumors with BRCA and other DNA damage repair alterations, including ovarian, breast and pancreatic cancers. These inhibitors include AstraZeneca's olaparib, GlaxoSmithKline's niraparib, Pfizer's talazoparib and Clovis’ rucaparib. He added, “We estimate these four drugs generated over $1.6 billion in worldwide sales in 2019 and are expected to reach over $6 billion in sales by 2024.”It should be noted that multiple IND filings are set to come within the next 4-12 months, with IDYA’s lead SL candidate, IDE397, which was designed to inhibit MTAP and MAT2A and thus cause the death of cancerous tumor cells, entering the clinic in 2021.It should come as no surprise, then, that Chiang joined the bulls. To start off his IDYA coverage, he puts an Outperform rating and $28 price target on the stock. This target implies a possible twelve-month rise of 141% could be on the horizon. (To watch Chiang’s track record, click here)Similarly, the rest of the Street is getting onboard. 5 Buy ratings assigned in the last three months add up to a Strong Buy analyst consensus. In addition, the $25.20 average price target puts the potential twelve-month gain at 116%. (See IDYA stock analysis on TipRanks)Ocular Therapeutix (OCUL)Using its patented bioresorbable hydrogel-based formulation technology, Ocular Therapeutix develops cutting-edge therapies for diseases and conditions of the eye. The progress of its clinical programs has caught Wall Street’s attention, with some arguing that now is the time to get in on the action.Griffin and Citadel didn’t want to miss out on an opportunity. Snapping up 161,032 shares during Q2, the hedge fund gave the holding a 272% boost. The total position is now comprised of 220,269 shares and is valued at $1,718,098.Representing Raymond James, 5-star analyst Dane Leone cites the potential to address the unmet needs in the dry eye disease indication as a key component of his bullish thesis. The company boasts two assets targeting the condition, OTX-CSI (chronic) and OTX-DED (acute). OTX-CSI incorporates the FDA-approved immunomodulator cyclosporine as the active drug in the intracanalicular insert, which is released for an estimated three months to increase tear production.When it comes to OTX-DED, Leone argues OCUL was “clever in pursuing the development of OTX-DED (a low dose form of DEXTENZA, a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus to deliver dexamethasone to the ocular surface for up to 30 days without preservatives) for the treatment of episodic dry eye, as the prior safety data from the DEXTENZA approval enabled management to file a Phase 2-enabling IND by YE20.”Speaking to the possible opportunity here, both products could “provide revenue generation for physicians in the treatment of dry eyes using procedure CPT code 0356T, which could provide incentive for rapid adoption in the dry eye space that is currently valued at $5.1 billion,” in Leone’s opinion.As for the clinical and regulatory pathway, the Phase 2 trial for OTX-DED is set to kick off in 2H21, slightly after OTX-CSI, which will see a Phase 2 clinical trial evaluating two different formulations initiated by 4Q20. Based on the short treatment duration of OTX-DED, management thinks it will still be brought to market first.To this end, Leone remains optimistic about the company’s long-term growth narrative. As a result, he rates OCUL a Strong Buy along with a $15 price target. This figure implies shares could rise 89% in the year ahead. (To watch Leone’s track record, click here) Turning now to the rest of the Street, other analysts are on the same page. With 100% Street support, or 3 Buy ratings to be exact, the consensus is unanimous: OCUL is a Strong Buy. The $13.50 average price target brings the upside potential to 70%. (See OCUL stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.